Literature DB >> 3806711

Natural course of the human bite wound: incidence of infection and complications in 434 bites and 803 lacerations in the same group of patients.

D Lindsey, M Christopher, J Hollenbach, J H Boyd, W E Lindsey.   

Abstract

Human bites and common lacerations are frequent in certain residential groups in institutions for the care of developmentally disabled individuals. We screened the records of such an institution and studied the course and outcome of 434 human bite wounds and 803 lacerations in the same group of clients. Infection developed in 13.4% of the lacerations, and 17.7% of the bite wounds (chi 2 = 3.474; p greater than 0.06). Prophylactic antibiotics were administered after 14.0% of the bite wounds, and 3.2% of the lacerations. Infection supervened after prophylactic antibiotics in 29.5% of the bites and 34.6% of the lacerations. No patient with a bite wound required debridement, initial or subsequent surgical intervention other than wound closure, admission to hospital, or intravenous antibiotics. There is no recorded instance of a bite wound complication other than immediate loss of tissue. These data substantiate a higher incidence of infection in human bite wounds, but they are scant support for admonition that such wounds are indication for routine antimicrobial prophylaxis or aggressive surgical intervention.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3806711

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  2 in total

1.  Management of bite wounds in children and adults-an analysis of over 5000 cases at a level I trauma centre.

Authors:  Manuela Jaindl; Gerhard Oberleitner; Georg Endler; Christiane Thallinger; Florian M Kovar
Journal:  Wien Klin Wochenschr       Date:  2015-12-11       Impact factor: 1.704

2.  The human bite injury: a clinical audit and discussion regarding the management of this alcohol fuelled phenomenon.

Authors:  Francis P Henry; Elizabeth M Purcell; Patricia A Eadie
Journal:  Emerg Med J       Date:  2007-07       Impact factor: 2.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.